Liver supplements: the rules and how to build one
In short
- A liver supplement with a health claim is a medicine, usually listed. Its liver claims sit in Part 5 (the gastrointestinal system) of the Permissible Indications Determination, and the detox claims in Part 1.
- The liver health claims must not imply or refer to liver disease, such as cirrhosis or hepatitis. Detox claims must refer only to natural body processes, and must not imply or refer to drugs or alcohol, or to disease in any organ.
- "Hepatoprotectant/protect the liver" also must not encourage excessive or harmful drinking. Several liver claims rest on traditional evidence only.
- Milk thistle, globe artichoke and dandelion are permitted actives with no specific requirements. Turmeric and green tea carry a warning that, in rare cases, they may harm the liver.
- From our records: a liver formula among the nine products we developed and quoted for an established natural health company.
Why a liver supplement is a medicine
A capsule, tablet or powder presented for a therapeutic use, such as supporting liver health, is a medicine, and most are listed medicines (AUST L). Every ingredient comes from the Permissible Ingredients Determination, every claim from the Permissible Indications Determination, and the sponsor holds the evidence for each before the product is sold (TGA approval).
The liver claims a listed medicine can make
Under section 6 of the Therapeutic Goods (Permissible Indications) Determination (No. 1) 2025, a claim can only be used if it is supported by the type of evidence its item names, and its requirements must be met (permitted indications). The liver claims in Part 5 include:
| Claim (as worded in the Determination) | Where | Evidence | Requirements |
|---|---|---|---|
| Maintain/support liver health | Part 5, item 117 | Scientific or traditional | Must not imply or refer to liver disease, such as cirrhosis, hepatitis |
| Maintain/support healthy liver function | Part 5, item 110 | Scientific or traditional | As above |
| Helps enhance/promote healthy liver function | Part 5, item 77 | Scientific or traditional | As above |
| Hepatoprotectant/protect the liver | Part 5, item 92 | Scientific or traditional | As above, and must not encourage excessive or harmful consumption of alcohol or other toxic substances |
| Liver tonic/Enhance liver health | Part 5, item 94 | Traditional only | As for item 117 |
| Aid/assist healthy liver regeneration | Part 5, item 7 | Traditional only | As for item 117 |
| Tonify/nourish/strengthen/replenish liver | Part 5, item 141 | Traditional only | As for item 117 |
| Maintain/support bile production | Part 5, item 95 | Scientific or traditional | None |
| Helps maintain/support bile secretion/flow | Part 5, item 79 | Scientific or traditional | None |
| Maintain/support gallbladder health | Part 5, item 101 | Scientific or traditional | Must not imply or refer to disease in any body organ |
Where the evidence is traditional, the claim carries a traditional context qualifier on the label, under section 6. The traditional Chinese and Ayurvedic Parts, 14 and 15, have liver claims of their own, such as "Yakrit uttejana/promote healthy liver function".
Detox claims
The detox claims sit in Part 1. "Maintain/support natural liver cleansing/detoxification processes" (item 139) can rest on scientific or traditional evidence, as can the body, gut and kidney versions. Every one of them carries the same three requirements:
- the product presentation must only refer to detoxification in relation to natural body processes
- it must not imply or refer to drugs or alcohol
- it must not imply or refer to disease in any body organ, in particular the kidney or liver.
So a liver product can't be presented as a hangover cure or a cleanse after drinking, on the pack, the website or social posts. The label is advertising too, and the same rules run through every ad (TGA advertising).
Liver ingredients and their warnings
The Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, in force since 16 October 2026, sets each ingredient's purposes and limits (permissible ingredients):
- Silybum marianum (milk thistle, item 4540), Cynara scolymus (globe artichoke, item 1680) and Taraxacum officinale (dandelion, item 4867): permitted as actives, with no specific requirements in their entries.
- Curcuma longa (turmeric, item 1646): when used in an oral medicine as an active ingredient, the label must carry the warning "In very rare cases, Curcuma species may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine, or itching." The entry also limits curcumin for children and teenagers by age, and turmeric isn't permitted for children under 2. Curcumin itself (item 1649) carries the same warning.
- Camellia sinensis (green tea, item 1133): in oral medicines, the label must carry "In rare cases, Camellia sinensis may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes, or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine, or itching." and "To be taken with food.", with exceptions set in the entry for some aqueous extracts and flavours. Caffeine is a mandatory component, with its own limits and warnings (energy and focus supplements).
A liver formula with turmeric or green tea carries a warning about the liver on its own label, so the claims and the warning are checked together at the brief. An ingredient that isn't in the Determination needs an application to the TGA first (new ingredients).
From our records
- An established natural health company: with a multi-product range and export customers. Across the relationship we developed and quoted nine products for the brand, spanning eye health, omega-3s, probiotics, liver, immune, prostate and more, and took three into production. Its eye-health formula kept failing in encapsulation, so we moved it to a direct-compression tablet, with stability for a three-year expiry, shipped in 2024.
- The Belly Solution: a gut-health product, from the same Part of the Determination as the liver claims. A travel gut-health powder in a 14-day pouch, combining Saccharomyces boulardii, a prebiotic and electrolytes, TGA-listed, about eight months from formulation to dispatch.
Questions
Frequently asked questions
It can claim to "Maintain/support natural liver cleansing/detoxification processes", from Part 1 of the Permissible Indications Determination. The presentation must only refer to natural body processes, and must not imply or refer to drugs, alcohol or disease in any organ.
No. The detox claims must not imply or refer to drugs or alcohol, and "Hepatoprotectant/protect the liver" must not encourage excessive or harmful consumption of alcohol.
Yes. Silybum marianum is a permissible active ingredient, with no specific requirements in its entry.
The Permissible Ingredients Determination requires it. An oral medicine with Curcuma longa as an active must say that in very rare cases Curcuma species may harm the liver, and list the symptoms to stop and see a doctor for.
No. The liver health claims require that the presentation not imply or refer to liver disease, such as cirrhosis or hepatitis.
Keep reading
Keep reading
Extending a supplement range: your next product, and the one after
Supplement range extension in Australia: what each new product needs from the TGA, what carries over from your first, and how brands we work with grew.
How long does it take to develop a supplement?
How long it takes to develop a supplement, from our records: 32 days from design to production order at the fastest, the stages, and what holds a launch up.
Stability testing and shelf life for supplements: what the TGA expects
Shelf life testing for listed medicines: the stability evidence the TGA expects, real-time and accelerated studies, ongoing testing and failed results.
How much does it cost to develop a supplement in Australia?
Cost to develop a supplement in Australia: the development stages, the TGA's fees and charges for 2026–27, minimum orders, cost of goods and what adds to it.
Sources
General information, checked against these sources on 16 November 2026. It isn't advice on a particular product. Our work is from Take Friday Off's records.
- Therapeutic Goods (Permissible Indications) Determination (No. 1) 2025, section 6 and Schedule 1, Parts 1, 5 and 15, Federal Register of Legislation
- Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026, section 6 and Schedule 1, items 1133, 1646, 1649, 1680, 4540 and 4867, Federal Register of Legislation
